BALTIMORE - TNF Pharmaceuticals, Inc. (NASDAQ:TNFA), a biopharmaceutical company specializing in autoimmune and inflammatory conditions, has announced the successful completion of a pivotal safety study for its drug isomyosamine, paving the way for larger and longer-term clinical trials. The study, which followed FDA guidelines, demonstrated safety over a 13-week period at various dosage levels.
This development enables TNF Pharmaceuticals to proceed with a Phase 2b trial assessing isomyosamine's effectiveness in treating sarcopenia, a muscle-wasting condition often associated with aging. The trial is set to commence early in the first quarter of 2025. The sarcopenia treatment market is expected to grow from $3.07 billion in 2024 to $4.02 billion by 2029, with a CAGR of 4.48%.
Additionally, the company is preparing to study the drug's potential in treating GLP-1-induced sarcopenia and frailty. GLP-1 agonists, currently a $49.3 billion market, are projected to double by 2029, highlighting the significance of addressing muscle loss associated with these treatments.
Isomyosamine, also known as MYMD-1®, is a novel small molecule that modulates the immune system by controlling TNF-alpha, a key inflammatory cytokine. The drug is being developed for conditions marked by inflammation, with the global TNF inhibitor market estimated at $39.7 billion in 2024 and expected to reach $47.3 billion by 2029.
The company's progress is part of its broader mission to develop therapies that treat the causes of diseases rather than just the symptoms. Alongside isomyosamine, TNF Pharmaceuticals is developing another platform, Supera-CBD, aimed at treating chronic pain, addiction, and epilepsy.
The press release includes forward-looking statements that involve risks and uncertainties, and actual results may differ materially from those projected. The company does not assume any obligation to update these statements. This article is based on a press release statement from TNF Pharmaceuticals, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.